Soligenix

Soligenix Net Debt/Equity

The Net Debt to Equity Ratio of Soligenix (SNGX) as of Oct 16, 2026 is -1.43. In the previous year, Net Debt to Equity Ratio was -1.54 — a change of -6.91% (higher).

Net Debt/Equity

-1.43

YoY

-6.91%

Last updated:

Net Debt to Equity Ratio of Soligenix is 2025 -1.43 . Net Debt to Equity Ratio of Soligenix was 2024 -1.54 . It decreases by -6.91% higher compared to the previous year.

The Soligenix Net Debt/Equity history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Net Debt/Equity
Date
Net Debt/Equity
Jan 1, 2017
-1.24 USD
Jan 1, 2019
-3.63 USD
Jan 1, 2020
-2.18 USD
Jan 1, 2021
-1.50 USD
Jan 1, 2022
1.26 USD
Jan 1, 2023
-1.96 USD
Jan 1, 2024
-1.54 USD
Jan 1, 2025
-1.43 USD
The Soligenix Net Debt/Equity history
YEARNet Debt/EquityYoY
-1.43-6.91%
-1.54-21.64%
-1.96-255.49%
1.26-184.18%
-1.50-31.31%
-2.18-39.89%
-3.63+193.98%
-1.24+4.20%
-1.19-100.47%
252.82+2,141.72%
11.28—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Soligenix Stock analysis

What does Soligenix do? Soligenix Inc, trading under the ticker SNGX, is a biotechnology company based in Princeton, New Jersey. The company has an IPO date of April 4, 1994, and currently employs 13 people. Soligenix operates in the health care sector, specifically within biotechnology. The company focuses on developing and commercializing treatments for rare diseases. Its business segments include Specialized BioTherapeutics and Public Health Solutions. Under Specialized BioTherapeutics, Soligenix is developing SGX301, a photodynamic therapy using topical synthetic hypericin activated by visible light for cutaneous T-cell lymphoma (CTCL). The Public Health Solutions segment encompasses development programs for RiVax, a ricin toxin vaccine candidate, and SGX943, a therapeutic candidate targeting antibiotic-resistant and emerging infectious diseases. The company also references CTCL as an innate defense regulator technology, though this appears to be a misstatement as CTCL is a disease, not a technology. Soligenix's website is https://www.soligenix.com/. Soligenix is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Soligenix stock

Net Debt to Equity Ratio of Soligenix is -1.43 in 2025.

Net Debt to Equity Ratio of Soligenix changed from -1.54 to -1.43, representing a -6.91% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Net Debt to Equity Ratio Soligenix since 2006 – with annual values, charts, and detailed analysis.

Net Debt/Equity adjusts the debt-to-equity ratio by subtracting cash from total debt. It provides a more accurate picture of actual leverage.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Net Debt to Equity Ratio's Soligenix with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Leverage — Soligenix

All Key Metrics — Soligenix